This picture taken on February 6 shows a logo of Japan’s SoftBank at their mobile shop in Tokyo.
9:00 JST, February 9, 2023
TOKYO (AFP-Jiji) — SoftBank Group on Tuesday reported a surprise $5.9 billion net loss in the third quarter, as a slump in the tech sector continued to hit the investment behemoth’s bottom line.
The loss compared with the net profit of ¥29 billion ($219 million) the firm reported in the same three-month period last year.
Its two Vision Fund investment vehicles alone lost ¥660 billion ($5 billion) in October-December, “reflecting declines in the share prices of a wide range of portfolio companies,” SoftBank said.
The firm has made huge bets to find and grow hot new tech ventures around the world, but that has left its earnings vulnerable to fickle market forces, and its Vision Funds have reported losses for four straight quarters.
Interest rate hikes by the U.S. Federal Reserve and other central banks to tackle inflation have weighed on global tech shares, putting pressure on SoftBank.
“In the past year or so, the environment has been very tough,” chief financial officer Yoshimitsu Goto told reporters.
“We cannot be optimistic yet,” Goto said.
Top Articles in Business
-
Nippon Life Insurance’s U.S. Arm Sues OpenAI Over Legal Assistance Provided by ChatGPT
-
Japan, U.S. Name 3 Inaugural Investment Projects; Reached Agreement After Considerable Difficulty
-
Japan’s Major Real Estate Firms Expanding Overseas Businesses to Secure Future Growth, Focusing on Europe, U.S., Asia
-
JR Tokai Breaks Ground on Yamanashi Maglev Station; Will Be Part of Linear Chuo Shinkansen Line from Tokyo to Nagoya
-
Transport Companies See Opportunity in Narita Expansion; Airlines, Railways Prepare to Meet Expected Growth in Demand
JN ACCESS RANKING
-
Producer Behind Pop Group XG Arrested for Cocaine Possession
-
Japan PM Takaichi’s Cabinet Resigns en Masse
-
Man Infected with Measles Reportedly Dined at Restaurant in Tokyo Station
-
Japan Figure Skating Legend Yuzuru Hanyu Is Proud Disaster Survivor and Gold Medalist, Vows to Continue Support Efforts
-
iPS Treatments Pass Key Milestone, but Broader Applications Far from Guaranteed

